Drug
XL647 clinical trials
Also written KD019, XL647 and Tesevatinib.
- studies test it
- 14
- open now
- 0
- in phase 3
- 1
- first study started
- 2004
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2006 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 8
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 1
Kadmon Corporation, LLC (10) · Kadmon, a Sanofi Company (2) · Exelixis (1) · NYU Langone Health (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses XL647 is read from its arms, and is right about nine times in ten.
Testing it · 14
- Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKDCompletedPhase 2Kadmon, a Sanofi CompanyNCT03203642Written as Tesevatinib
- A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney DiseaseCompletedPhase 1/2Kadmon, a Sanofi CompanyNCT01559363Written as Tesevatinib
- Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101TerminatedPhase 2Kadmon Corporation, LLCNCT02616055Written as tesevatinib
- Study of XL647 in Subjects With Non-Small-Cell Lung CancerCompletedPhase 2Kadmon Corporation, LLCNCT00364780Written as XL647
- Study of XL647 Administered Orally Daily to Patients With Solid TumorsCompletedPhase 1Kadmon Corporation, LLCNCT00336765Written as XL647
- Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid TumorsCompletedPhase 1Kadmon Corporation, LLCNCT00086528Written as XL647
- Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or ErlotinibCompletedPhase 2Kadmon Corporation, LLCNCT00522145Written as XL647
- KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line ChemotherapyTerminatedPhase 3Kadmon Corporation, LLCNCT01487174Written as KD019
- A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)CompletedPhase 1Kadmon Corporation, LLCNCT03096080Written as Tesevatinib
- Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast CancerTerminatedPhase 1/2Kadmon Corporation, LLCNCT02154529Written as Tesevatinib
- Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal MetastasesCompletedPhase 2Kadmon Corporation, LLCNCT02616393Written as Tesevatinib
- Study of Tesevatinib Monotherapy in Patients With Recurrent GlioblastomaCompletedPhase 2Kadmon Corporation, LLCNCT02844439Written as Tesevatinib
- Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid TumorsWithdrawnPhase 1ExelixisNCT00704392Written as XL647
- KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach CancerWithdrawnPhase 1NYU Langone HealthNCT02205463Written as KD019
Codes
What other systems call XL647 · ClinicalTrials.gg INT006048
- MeSH (NLM) C571826XL647Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) F6XM2TN5A1TESEVATINIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C571826 | XL647 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | F6XM2TN5A1 | TESEVATINIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.